PD-L1 expression is exploited by various tumor cells, including gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, pancreatic cancer, and ovarian cancer cells, to subvert T-cell-mediated immunosurveillance (27). This evidence concerns the gene CD274 and hepatocellular carcinoma.